BioPharma Resources

Therapeutic area

Psychiatry

Depression, schizophrenia, bipolar disorder, ADHD and addiction. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

7

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

50

Industry-sponsored

Recruiting Phase 3

69

Industry-sponsored

Recruiting Phase 4 (post-approval)

6

Industry-sponsored

Recent approvals

All
  • Bysanti (Milsaperidone) · Vanda Pharms INC NovelFeb 20, 2026

    To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder

  • Cobenfy (Trospium Chloride, Xanomeline Tartrate) · Bristol-Myers NovelSep 26, 2024

    To treat schizophrenia

  • Opipza (Aripiprazole) · Xiamen Lp Pharm CO Jul 22, 2024
  • Exxua (Gepirone Hydrochloride) · Fabre Kramer NovelSep 22, 2023

    To treat major depressive disorder

  • Zurzuvae (Zuranolone) · Biogen NovelPriority reviewAug 4, 2023

    To treat postpartum depression

  • Uzedy (Risperidone) · Teva Apr 28, 2023
  • Abilify Asimtufii (Aripiprazole) · Otsuka Apr 27, 2023

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • BrenipatideLY3537031Phase 313 trials

    Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major

  • AzetukalnerXEN1101Phase 39 trials

    Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder

  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • SEP-363856UlotarontPhase 37 trials

    Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder

  • BHV-7000Phase 36 trials

    Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder

  • ITI-1284JNJ-99245354Phase 36 trials

    Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders

  • MazdutideLY3305677Phase 35 trials

    Eli Lilly · Type 2 Diabetes, Obesity, Overweight

  • NBI-1065845TAK-653, OsavampatorPhase 35 trials

    Neurocrine Biosciences · Major Depressive Disorder

  • NBI-1117568Phase 35 trials

    Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania

  • RAP-219Phase 35 trials

    Rapport Therapeutics Inc. · Focal Epilepsy, Epilepsy, Focal Seizure

  • ACP-204Phase 34 trials

    ACADIA Pharmaceuticals Inc. · Alzheimer's Disease Psychosis, Lewy Body Dementia Psychosis

  • CebranopadolTRN-228Phase 34 trials

    Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain

  • CYM-53093Navacaprant, NMRA-335140Phase 34 trials

    Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder

  • DT120MM120, lysergide tartratePhase 34 trials

    Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder

  • KH607Phase 34 trials

    Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Major Depressive Disorder (MDD), Postpartum Depressive Disorder

Largest recruiting Phase 3 trials

All

More: Psychiatry news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.